2nd Quarter - Report

NOVO NORDISK INC. for NOVO NORDISK INC.

Firm
Client
Income
—
Expenses
$900,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP): biosimilar provisions

Contacted: HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); White House Office; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE

Taxation/Internal Revenue Code TAX

H.R. 436 Protect Medical Innovation Act of 2011

Contacted: Health & Human Services, Dept of (HHS); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Executive Office of the President (EOP); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL)

Bills named: H.R. 436 (112th)

Health Issues HCR

P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: biosimilar provisions

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; White House Office; Food & Drug Administration (FDA); Labor, Dept of (DOL); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; CMS Proposed Coverage Decision Memorandum for Intensive Behavioral Therapy for Obesity; Medicare Diabetes Screening; HR 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Medicaid coverage of obesity counseling and expanding provider type; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 (deficit reduction)

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); White House Office; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Labor, Dept of (DOL); SENATE

Bills named: H.R. 2741 (112th)

Budget/Appropriations BUD

S. 3295 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program); Issues related to modernizing cost estimates with respect to preventive health legislation (scoring) and National Diabetes Prevention Program

Contacted: Food & Drug Administration (FDA); SENATE; Natl Institutes of Health (NIH); Executive Office of the President (EOP); White House Office; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL)

Bills named: S. 3295 (112th)

Law Enforcement/Crime/Criminal Justice LAW

S. 1002 SAFE DOSES Act and HR 4223 Safe Doses Act (Modernizing criminal laws concerning theft of medical products)

Contacted: Health & Human Services, Dept of (HHS); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Labor, Dept of (DOL); Executive Office of the President (EOP)

Bills named: H.R. 4223 (112th), S. 1002 (112th)

Pharmacy PHA

P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues regarding comparative effectiveness, implementation of Physician Payment Sunshine provisions and Prescription Drug Sample reporting provisions; S.3187 FDA Safety and Innovation Act (PDUFA V); H.R. 4274 Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act; H.R. 3026 Safeguarding America's Pharmaceuticals Act of 2011; Pharmaceutical Traceability Enhancement Code (Rx TEC) Act; H.R. 5973 FY2013 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (FDA funding); 340B

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); White House Office; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: H.R. 4274 (112th), H.R. 3026 (112th), H.R. 5973 (112th), S. 3187 (112th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
NOVO A/S Denmark Denmark 25.5% —
NOVO NORDISK FONDEN (FOUNDATION) Denmark Denmark 25.5% —
NOVO NORDISK A/S Denmark Denmark 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.